IDE034 for advanced solid tumors with B7-H3 or PTK7
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have one of these cancers that has spread or come back: lung, esophageal, endometrial, ovarian, head and neck, triple-negative breast, colorectal, or prostate cancer.
- Your cancer has gotten worse or you couldn't handle at least one standard treatment.
- You have a tumor sample available from a past surgery or biopsy.
- You can do daily activities without help (like walking or light housework).
- Important: You cannot have brain tumors that cause symptoms, or certain heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
This study tests a new drug called ES014 for people with advanced solid tumors that can't be removed or have spread. It's an early trial to see if ES014 is safe and helps fight certain cancers.
This trial tests a new drug called DAY301 for people with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and if it can shrink tumors.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.